These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33899548)

  • 1. NMR Reporter Assays for the Quantification of Weak-Affinity Receptor-Ligand Interactions.
    Almeida TB; Panova S; Walser R
    SLAS Discov; 2021 Sep; 26(8):1020-1028. PubMed ID: 33899548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [NMR screening in fragment-based drug discovery].
    Hanzawa H; Takizawa T
    Yakugaku Zasshi; 2010 Mar; 130(3):325-33. PubMed ID: 20190517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating protein-ligand binding affinity using high-throughput screening by NMR.
    Shortridge MD; Hage DS; Harbison GS; Powers R
    J Comb Chem; 2008; 10(6):948-58. PubMed ID: 18831571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biophysical screening for the discovery of small-molecule ligands.
    Ciulli A
    Methods Mol Biol; 2013; 1008():357-88. PubMed ID: 23729259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of Solution NMR in Drug Discovery.
    Shi L; Zhang N
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33499337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMR approaches in structure-based lead discovery: recent developments and new frontiers for targeting multi-protein complexes.
    Dias DM; Ciulli A
    Prog Biophys Mol Biol; 2014; 116(2-3):101-12. PubMed ID: 25175337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical aspects of NMR-based fragment discovery.
    Zartler ER; Mo H
    Curr Top Med Chem; 2007; 7(16):1592-9. PubMed ID: 17979770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current NMR Techniques for Structure-Based Drug Discovery.
    Sugiki T; Furuita K; Fujiwara T; Kojima C
    Molecules; 2018 Jan; 23(1):. PubMed ID: 29329228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMR-Fragment Based Virtual Screening: A Brief Overview.
    Singh M; Tam B; Akabayov B
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29370102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding site identification and structure determination of protein-ligand complexes by NMR a semiautomated approach.
    Ziarek JJ; Peterson FC; Lytle BL; Volkman BF
    Methods Enzymol; 2011; 493():241-75. PubMed ID: 21371594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of NMR and molecular docking in structure-based drug discovery.
    Stark JL; Powers R
    Top Curr Chem; 2012; 326():1-34. PubMed ID: 21915777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A three-stage biophysical screening cascade for fragment-based drug discovery.
    Mashalidis EH; Śledź P; Lang S; Abell C
    Nat Protoc; 2013 Nov; 8(11):2309-24. PubMed ID: 24157549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient affinity ranking of fluorinated ligands by
    Rüdisser SH; Goldberg N; Ebert MO; Kovacs H; Gossert AD
    J Biomol NMR; 2020 Nov; 74(10-11):579-594. PubMed ID: 32556806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
    Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
    Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fast Quantitative Validation of 3D Models of Low-Affinity Protein-Ligand Complexes by STD NMR Spectroscopy.
    Nepravishta R; Ramírez-Cárdenas J; Rocha G; Walpole S; Hicks T; Monaco S; Muñoz-García JC; Angulo J
    J Med Chem; 2024 Jun; 67(12):10025-10034. PubMed ID: 38848103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficiently driving protein-based fragment screening and lead discovery using two-dimensional NMR.
    Peng C; Namanja AT; Munoz E; Wu H; Frederick TE; Maestre-Martinez M; Iglesias Fernandez I; Sun Q; Cobas C; Sun C; Petros AM
    J Biomol NMR; 2023 Apr; 77(1-2):39-53. PubMed ID: 36512150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polarization Transfer from Ligands Hyperpolarized by Dissolution Dynamic Nuclear Polarization for Screening in Drug Discovery.
    Min H; Sekar G; Hilty C
    ChemMedChem; 2015 Sep; 10(9):1559-63. PubMed ID: 26315550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass spectrometry for fragment screening.
    Chan DS; Whitehouse AJ; Coyne AG; Abell C
    Essays Biochem; 2017 Nov; 61(5):465-473. PubMed ID: 28986384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.